Table 1.
Ancestral proportions of commonly used human cancer cell lines
| Cell Line | ATCC Catalog No. | Gender | Age | Tissue | Designated Race/Ethnicity | WA | NA | EUR | Putative Ancestry |
|---|---|---|---|---|---|---|---|---|---|
| PC3 | CRL-1435 | M | 62 | Prostate Cancer | White/EA | 0.3% | 0.4% | 99.3% | EA |
| DU145 | HTB-81 | M | 69 | Prostate Cancer | White/EA | 0.4% | 0.5% | 99.1% | EA |
| LNCaP | CRL-1740 | M | 50 | Prostate Cancer | White/EA | 6.5% | 1.9% | 91.7% | EA |
| RWPE1 | CRL-11609 | M | 54 | Prostate Cancer | White/EA | 2.2% | 1.7% | 96.1% | EA |
| 22Rv1 | CRL-2505 | M | N/A | Prostate Cancer | N/A | 0.3% | 0.4% | 99.3% | EA |
| E006AA-hT | CRL-3277 | M | 50 | Prostate Cancer* | Black/AA | 1.3% | 7.4% | 91.3% | EA |
| MDA-PCa-2b | CRL-2422 | M | 63 | Prostate Cancer | Black/AA | 86.5% | 3.0% | 10.6% | AA |
| RC-77T/E | N/A | M | 63 | Prostate Cancer | Black/AA | 88.9% | 0.4% | 10.7% | AA |
| HeLa | CCL-2 | F | 31 | Cervical Cancer | Black/AA | 66.5% | 0.4% | 33.1% | AA |
| MCF-10A | CRL-10317 | F | 36 | Breast Disease | White/EA | 0.9% | 2.4% | 96.7% | EA |
| MDA-MB-453 | HBT-131 | F | 48 | Breast Cancer | White/EA | 0.2% | 0.4% | 99.4% | EA |
| HCC1500 | CRL-2329 | F | 32 | Breast Cancer | Black/AA | 78.8% | 0.5% | 20.7% | AA |
| HCC1806 | CRL-2335 | F | 60 | Breast Cancer | Black/AA | 80.2% | 4.4% | 15.4% | AA |
| MDA-MB-468 | HTB-132 | F | 51 | Breast Cancer | Black/AA | 77.1% | 22.7% | 0.2% | AA/HA |
| T-47D | HTB-133 | F | 54 | Breast Cancer | N/A | 0.1% | 0.3% | 99.7% | EA |
*
E006AA-hT is sold by ATCC as a prostate cancer cell line; however, ATCC acknowledges that the STR profile of this cell line is an 86% match to the 786-O renal cell carcinoma cell line (44).
F, female; M, male; AA, African American; EA, European American; HA, Hispanic American; N/A, not available; No., number; WA, West African; NA, Native American; EUR, European